Bionor Pharma ASA issues shares to board members

(Oslo, Norway, 23 June 2015) In accordance with the resolution by the Annual General Meeting of Bionor Pharma ASA (OSE: BIONOR) on 13 May 2015, all board members have been offered to subscribe shares in the Company valued at NOK 100,000 and the Chairman of the Board has been offered to subscribe shares valued at NOK 200,000.

The number of shares offered was calculated on the basis of the volume weighted average share price the 4 weeks preceding the Annual General Meeting being NOK 2.80. On this basis the Board members were offered to subscribe 35,215 new shares at a subscription price of NOK 0.25 and the Chairman 70,430 new shares at a subscription price of NOK 0.25. All board members have accepted the offer and the Company will accordingly issue 316,935 new shares at par value NOK 0.25 and thus increase the issued share capital by NOK 79,233.75.

The share issue will take place as soon as payment has been received and the share capital increase is registered in the Companies Register. Following the share issue the members of the Board of Directors will directly and indirectly hold the following shares: 

Name

No. of shares

Russell G. Greig

70,430

Øystein Soug, subscribing through
Abacus Invest AS

142,420

Benedicte Fossum, subscribing through Mittas AS

71,578

Jerome B. Zeldis

267,215

Marianne Kock

42,684

Bernd R. Seizinger

35,215

Thomas Hofstaetter

35,215

Kirsten Drejer

35,215

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


Contact
Jørgen Fischer Ravn, Vice President for Investor Relations & Communications

Phone: +45 2030 3903

jfr@bionorpharma.com

About Bionor

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company's focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma’s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study.

Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York, and is listed on the Oslo stock exchange, under the ticker BIONOR. More information about Bionor is available at www.bionorpharma.com.